Christopher Senner, EVP and CFO of Exelixis, sold 34,901 shares on May 18, 2026, totaling $1,745,050.
Shares were sold at prices ranging from $50.00 to $50.07. After the sale, Senner directly holds 952,317 shares.
The company maintains excellent financial health with a 41% return on equity. Bond.az analysis suggests the stock remains undervalued.
On May 15, 40,892 shares were withheld for tax obligations related to RSU vesting, valued at $2,089,581.
In Q1 2026, Exelixis beat expectations with EPS of $0.87. The company also entered a clinical collaboration with Merck for colorectal cancer.
